Related articles

  • Article

    Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

    Clin Cancer Res. 2007 Aug 1; 13 (15 Pt 1): 4556-64.

  • Article

    Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.

    Clin Cancer Res. 2011 Jul 15;17(14):4672-81.

  • Article

    Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.

    Clin Cancer Res. 2006 Jan 1; 12 (1): 242-9.

    • Show more related articles...